Voor de liefhebbers van Nektar onder ons verwijs ik jullie naar het volgende commentaar bij het SA stuk terzake dat 16 feb on line gekomen is:
Corey(If I may call you Corey), you lose creditability when you post---" Because you wouldn't waste your time here hammering your point on insider selling if you weren't short. There's just no reason for it. Especially when you say "selling every share they have" which is not true.... the CEO still has nearly half a million shares and many are also buying. Please stop posting untruths.” As for you touting the ownership by Invesco indicates you might be a novice when it comes to understanding how the market works. Let me explain, in a country boy’s vernacular, something you might need to understand—“You can skin a cat more than one way!” Have you not been sitting up and paying attention to the markets recently—what about the new SPACs and Redditt shenanigans? A lot of cats are being skinned, my boy!
Now before you throw out your charge that I’m shorting NKTR--- you are the one not being truthful! In fact, if you go back eight years ago, you will see I was one of the first SA contributors that wrote about NKTR. In fact, I hold an exceedingly small position in NKTR—and contrary to what you might say about me, I venture that I have a unique understanding of the history of this company. Corey, I’ve actual attended an FDA meeting involving one of NKTR drugs being reviewed for approval.
Speaking of approval and the merits of PEG, you do realize that NKTR has been around for decades—so quickly tell me how many drugs have been developed and approved using NKTR’s “novel” technology? You brought up Pfizer--- do you realize how many “B”illions they lost in trying to market the original FDA approved NKTR drug? Remember, the FDA meeting I attended---the FDA voted to approve the drug (Movitak) and Astra signed on to market the drug—guess what? You did read the recent news that NKTR unloaded several drugs for a bag of peanuts and a Blatz beer—because they could not get any doctor or patients using their drugs. The only thing consistent coming from NKTR management---issue themselves options, convert them and unload them on novice investors! Two decades and what has NKTR done for shareholders—zilch, if not an insider!
Good luck with your future investing decisions!
And the answer is –YES! I’m just an ol’ country boy! And I like cats and hate to see them mistreated!
Redelijk kritisch dunkt me. Wat voor nieuwe ontwikkelingen zijn er die de huidige upswing zouden moeten rechtvaardigen? De deal met Merck? Als dat zo is zou Affimed nu ook al het dubbele van de huidige aarde moeten hebben. Dat Invesco daar nog steeds 19% van de aandelen heeft zegt mij niet zo veel. Er zijn meer voorbeelden van grote investeerders die jaren aan een dood paard hebben zitten trekken.